STUDY SOMES PROGNOSTICS FACTORS OF CUTANEOUS MELANOMA AT K HOSPITAL FROM 2009 TO 2019

Vũ Thanh Phương1,, Nguyễn Văn Chủ1, Nguyễn Đại Bình1
1 K Hospital

Main Article Content

Abstract

Objective: Study on clinical,histopathological featuresand some prognostic factors of cutaneous melanoma. Subjects and methods: A retrospective and prospective  study on 207 cutaneous melanoma patients in stage II, III were treated with surgery at K hospital from 2009 to 2019. Results: The average age is 55,0 ± 0,9, which is common from 40 to 79 years, youngest patient 18 years-old and the oldest one 85 years-old, female/male 1,13. Tumors are often located in the lower limbs, superficial spreading melanoma 61,7%, thickness 2,1-4,0mm 29,8%, > 4,0mm 67,4%. Clark V 51,8%, Clark IV 34%, the vertical development stage 75,2 %, satellite  30,5%, ulcer 43,2%, invasion to blood vessel 22%. In tumors invade mesoderm, mitosis > 6/mm2 38,3%, sparse invasive lymphocytesgroup 33,3%, without invasive lymphocytes group 36,2 %. Lymph node metastasis 45,9%, stage 2, 3 is 45,9%, 54,1%. The overall 5-year survival rate is 42.4%. Prognostic factors affect the overall 5-year survival rate: tumor location, histopathological type, thickness, Clark, developmental stage, satellite, ulcer, invasion to blood vessel, invade mesoderm, invasive lymphocytes, number of lymph nodes metastasis and stage. Conclusion: Common age 40-70, female/male is 1,13, lower limbs 62,3%, superficial spreading melanoma 61,7%, >4,0mm 67,4%. Clark V 51,8%, the vertical development stage 75,2 %, satellite  30,5 %, ulceration 43,2%, invasion to blood vessel 22%, invade mesoderm, mitosis > 6/mm2 is 38,3%. Lymph node metastasis 45,9%, stage 2, 3 is 45,9%, 54,1%. The overall 5-year survival rate 42.4%. Prognostic factors: tumor location, histopathological type, thickness, Clark, developmental stage, satellite, ulcer, invasion to blood vessel, invade mesoderm, invasive lymphocytes, number of lymph nodes metastasis and stage.

Article Details

References

1. Albino A.P, Reed J.A., McNutt N.S et al. (1997). Molecular Biology of Cutaneous Melanoma, Principles and practice of Oncology. Lippincott Raven, 2, 46.
2. Marc Hurlbert (2020). 2020 Melanoma mortality rates decreasing despite ongoing increase in incidence. Melanoma research Alliance.
3. Phạm Hoàng Anh và cộng sự (1993), Ung thư Hà Nội 1991- 1992, y học Việt Nam; chuyên đề ung thư, tập 173, số 7, 14-21.
4. Balch CM, Joong SJ, et al. (2001). Prognostic factors analysis of 17.600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol,19(16), 3622-34.
5. Garbe C., Butner P., Bertz J. et al. (1995). Primary cutaneous melanoma, identification of prognostic group and estimation of individual prognostic for 6599 patients. Cancer, 75, 2484-91.
6. Clark WH Jr Elder DE, et al. (1989). Model predicting survival in stage I melanoma based on tumor progression. JNCI, 81, 1893 – 1904.
7. Barnhill RL, Fine JA, Roush GC, Berwick M. (1996). Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer, 78,427-432.